You Position: Home > Paper
Primary study on herceptin combined with DDP to the vivo action for culture of human ovarian cancer with Her-2/neu overexpression
( views:176, downloads:0 )
- Author:
- No author available
- Journal Title:
- CANCER RESEARCH AND CLINIC
- Issue:
- 5
- DOI:
- 10.3760/cma.j.issn.1006-9801.2006.05.004
- Key Word:
- Herceptin;顺铂;Her-2/neu;卵巢癌
Abstract： 目的筛选高表达Her-2/neu的卵巢癌细胞株,观察Herceptin联合顺铂(DDP)对该细胞株体外生长的抑制作用.方法采用反转录-聚合酶链反应技术,检测人卵巢癌细胞株3AO,SKOV3,OVCARHer-2/neu的表达情况,筛选出高表达Her-2/neu的人卵巢癌细胞株.采用四甲基偶氮唑蓝(MTT)法测定Herceptin,DDP以及联合用药对高表达Her-2/neu的人卵巢癌细胞株体外生长抑制率并进行比较.结果人卵巢癌细胞株SKOV3 Her-2/neu呈高表达;Herceptin可有效抑制SKOV3的生长,具有浓度依赖性(P=O.001),联合用药组的生长抑制率为79.41%,明显高于二者单独作用(P=0.0001).结论人卵巢癌细胞株SKOV3 Her-2/neu呈高表达.Herceptin,DDP均能有效抑制SKOV3的生长,联合用药组疗效更佳.
- [1]罗荣城,李爱民,张军一,等.Herceptin治疗Her-2过度表达的转移性乳腺癌[J].2004,(1).
- [2]M C, Hung,Y K, Lau.Basic science of HER-2/neu: a review.[J].1999,26.
- [3]H, Yang,G, Zhang,K, Xu.[c-erbB2 gene amplification in human primary epithelial ovarian cancer and its clinical significance].[J].1998,20(5).
- [4]Pietras R,Coombs D,Slamon D,etc.Inhibitory effects of combinations of HER-2/neu antibody and chemotherapeutic agents used for treatment of human breast cancers.[J].1999,18(13).
- [5]Karaaslan S,Turzynski A,Dietel M,etc.Suppression of the c-erbB-2 gene product decreases transformation abilities but not the proliferation and secretion of proteases of SK-OV-3 ovarian cancer cells.[J].1999,81(5).